INTRODUCTION
============

HIV/AIDS is characterized as a serious public health problem and is considered as a major challenge worldwide [@b1-cln_69p770]. According to the World Health Organization [@b2-cln_69p770], approximately 33.3 million people were infected with HIV/AIDS in 2009 and it is estimated that a total of 2.6 million individuals are infected annually. In 2010, these figures already exceeded 34 million infected individuals, including adults and children.

An infected person may not show any clinical symptoms that are suggestive of the infection for years. However, continued viral replication and the consequent decline in CD4+ T cells may lead to the onset of clinical manifestations. In addition, upon acquiring immunodeficiency, the infected person becomes susceptible to the development of other infections. In fact, bacterial infections are responsible for most of the events that affect HIV-infected patients [@b3-cln_69p770]. Although the use of antiretroviral therapy has improved this scenario, a few pathogens can cause clinical complications, such as *Staphylococcus aureus*. This pathogen, which has been identified as being responsible for morbidity and mortality among HIV patients, produces important virulence factors and frequently acquires resistance to different antibiotics [@b4-cln_69p770],[@b5-cln_69p770].

Methicillin-resistant *S. aureus* (MRSA) expresses an additional penicillin-binding protein, PBP2a, which is encoded by the *mec*A gene. This gene is located in a mobile genetic element referred to as staphylococcal chromosomal cassette *mec* (SCC*mec*) [@b6-cln_69p770]. SCC*mec* types II and III are commonly associated with hospital-acquired isolates, whereas community-acquired isolates normally carry type IV or V [@b7-cln_69p770],[@b8-cln_69p770].

Decreased host immunity among HIV-infected patients places them at increased risk for several infections, including those caused by *S. aureus* and MRSA. Certain authors have evaluated the risk factors related to infection and/or colonization of HIV-infected individuals with *S. aureus* and have shown the importance of various behavioral and clinical aspects [@b9-cln_69p770]-[@b11-cln_69p770]. However, only few studies have used microbiological methods to characterize isolates to validate of their data [@b9-cln_69p770],[@b10-cln_69p770]. Thus, this systematic review aimed to determine both the risk factors associated with colonization/infection by MRSA in HIV-infected individuals and the methods used for characterization of isolates.

MATERIALS AND METHODS
=====================

The present study may be characterized as a descriptive, exploratory and systematic literature review. This review was conducted by two examiners, who performed a non-biased analysis of the studies selected based on the inclusion and exclusion criteria described below.

The search covered articles published between January 2001 and December 2013 in five online health sciences databases: PubMed, the Scientific Electronic Library Online (SciELO), the Latin American and Caribbean Health Sciences (LILACS) database, Ovid, Google Scholar. The search was conducted using six keywords: "MRSA, methicillin-resistant *Staphylococcus aureus"*, "HIV", "*Staphylococcus*", "recurrent infections", "molecular typing" and "epidemiology". These keywords were selected as being reflective of the topic of interest, as analyzed previously using the Medline MeSH.

Articles were selected from each database based on the following inclusion criteria: a title and abstract compatible with the given subject; published within the last 13 years (from January 1, 2001 to December 31, 2013); published in Portuguese, English or Spanish; and based on original research. Articles were excluded when the main subject was not compatible with the aim of the present study (such as phytochemistry, biology of lymphocytes and kidney disease, among other topics); when they were published more than 13 years ago; when they dealt with *S. aureus*-related infections in bone or gynecological areas or with endocarditis, which have characteristics that distinguish them from other infections; when their links for online access had no data available for consultation; and when they were case reports, literature reviews, book chapters, theses or letters to the editor.

Papers that fulfilled the selection criteria were analyzed for their methodological quality using a quality assessment questionnaire based on criteria established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISM) statement. The scores for determining the presence of features regarded as important in the study are shown in [Table 1](#t1-cln_69p770){ref-type="table"}. In this classification, each item presented by a study corresponds to a score of one. The studies that received scores between 8 and 10 were classified as level A, which indicates high methodological quality and studies that had scores of 5 to 7 points were classified as level B, implying intermediate methodological quality. Meanwhile, scores of less than or equal to 4 points were included in level C, indicating low methodological quality. Only studies classified as level A were included in the current review.

RESULTS
=======

[Figure 1](#f1-cln_69p770){ref-type="fig"} outlines the steps for the selection of the studies. The number of articles found in and selected from the databases is listed in [Table 2](#t2-cln_69p770){ref-type="table"}. An initial electronic search of the health sciences databases using the keywords uncovered a total of 911, 29, 841, 11 and 1,115 articles from PubMed, SciELO, LILACS, Ovid and Google Scholar, respectively. After applying the inclusion and exclusion criteria, 67 studies were selected and analyzed for quality. The quality assessment revealed 9 papers in category A, which were included in the present systematic review ([Table 3](#t3-cln_69p770){ref-type="table"}). Of these papers, eight received 8 points and only one received 9 points. The data from the selected studies are listed in [Table 3](#t3-cln_69p770){ref-type="table"}. Among the most relevant data, the size of the target population was considered to be very discrepant, ranging from 107 to 4,674 patients.

The study designs were mostly retrospective (4/9 studies) and the most common risk factors associated with colonization/infection were previous use of antimicrobials (4/9 studies), previous hospitalization (4/9 studies) and the CD4+ T lymphocyte count (typically \<200 cells/μl) (3/9 studies) ([Table 3](#t3-cln_69p770){ref-type="table"}).

The main methodologies used for *S. aureus* phenotypic identification were culture in salt mannitol agar (3/9 studies) and the latex agglutination test (5/9 studies), which was used for the detection of the clumping factor or bound coagulase. Pulsed-field gel electrophoresis (PFGE) was the main molecular analytical method used to define the search community/hospital clones (6/9 studies) and the USA300 lineage was considered to be the most prevalent in the majority of the articles that assessed the clonality of isolates. The exception was a study performed by Gordon et al. (2010) from New York, USA, which found a larger number of isolates related to the USA500 lineage, a hospital clone.

Susceptibility, as determined by the disk diffusion test, was evaluated in only 3 of the 9 studies. However, 5 studies determined the minimum inhibitory concentration (MIC) or the susceptibility of isolates using an automated technique.

MRSA isolates were detected and analyzed by the authors of 6 of the 9 selected papers, whereas the other 3 studies were retrospective, evaluating data from laboratory and hospital databases. The studies that evaluated antimicrobial resistance described erythromycin-resistant *S. aureus* (3/9 studies), vancomycin-susceptible *S. aureus* (4/9 studies) and/or rifampicin-susceptible *S. aureus* (3/9 studies). Two studies also performed SCC*mec* typing and found that type IV was a common or unique cassette among MRSA isolates.

DISCUSSION
==========

The use of HAART has increased the life expectancy of HIV-infected patients, whether pediatric or adult, via the reduction of opportunistic infections, with a consequent improvement in quality of life [@b13-cln_69p770]. In this context, it remains unclear whether these patients have an increased risk of these microbial infections due to a higher prevalence of colonization by pathogens or due to other factors. Therefore, knowledge of the risk factors that may favor colonization is critical to develop strategies to prevent colonization and infection in patients and their contacts [@b4-cln_69p770],[@b9-cln_69p770],[@b14-cln_69p770],[@b15-cln_69p770]. In the current systematic review, both the risk factors associated with colonization/infection by MRSA in HIV-infected individuals and the methods for characterization of this pathogen were evaluated.

Among the 9 studies that qualified for this review, 2 were conducted in Europe and 7 were conducted in North America. In 4 of these studies, use of antibiotics was detected as an important risk factor for *S. aureus* infections in HIV-positive individuals [@b9-cln_69p770],. In addition, most of these isolates were MRSA, suggesting that the use of antibiotics can lead to the selection of resistant microorganisms. However, there was no consensus among the authors about previous exposure to antibiotics during sampling [@b9-cln_69p770],. Thus, although it has been well established that prior antimicrobial therapy is a risk factor for MRSA colonization/infection, it is difficult to determine exactly what duration of antibiotic use may be considered as a risk factor.

Previous hospitalization [@b15-cln_69p770],[@b18-cln_69p770],[@b19-cln_69p770] and invasive medical procedures [@b19-cln_69p770] were also described as risk factors for the acquisition of MRSA by HIV patients. In particular, a multivariate analysis showed that HIV patients hospitalized for more than five days had a 14% increased risk of acquiring MRSA [@b19-cln_69p770]. Other factors, such as diabetes [@b20-cln_69p770], previous infections or co-infections (including skin and soft tissue infections) [@b15-cln_69p770],[@b16-cln_69p770],[@b18-cln_69p770], co-morbidities [@b20-cln_69p770] and a history of colonization and infection by MRSA [@b15-cln_69p770], were also reported as risk factors for acquiring this pathogen.

Certain behavioral risk factors have also been associated with colonization by MRSA, including imprisonment [@b18-cln_69p770], alcohol abuse [@b18-cln_69p770], heterosexual behavior [@b20-cln_69p770], homelessness [@b18-cln_69p770] and illicit drug use [@b17-cln_69p770],[@b18-cln_69p770]. Although excluded based on its quality criteria, a study by Mimiaga et al. reported that crystal methamphetamine users are more likely to have multiple partners and to engage in risky sexual intercourse [@b21-cln_69p770]. Similarly, strong associations between HIV infection, use of injectable drugs and the development of bacteremia caused by MRSA have been shown [@b20-cln_69p770].

The samples selected for these types of studies should be clearly representative of the target population of HIV-infected individuals. However, in the present review, the majority of the studies selected their samples from a single institution, without sample calculation, which may be related to the convenience of sample collection or to a low number of cases. The resultant variation made the data analyses challenging. Moreover, certain studies used only one sample (one clinical specimen per patient), whereas others used more than one sample per patient [@b9-cln_69p770],[@b11-cln_69p770],[@b15-cln_69p770],[@b16-cln_69p770],[@b17-cln_69p770],, making the analysis difficult. Additionally, there were differences in the type of design used among the studies analyzed.

In the present review, nearly half of the articles (3/9 studies) used culture in selective media (mannitol salt agar), followed by the latex agglutination test, to identify *S. aureus* isolates. Although latex tests are simple and rapid, they do not present 100% sensitivity [@b24-cln_69p770] because other species, such as *S. lugdunensis*, that are positive for clumping factor may be misidentified as *S. aureus* using this test [@b25-cln_69p770]. In contrast, the coagulase tube test, which is a more reliable method for identifying *S. aureus*, was not performed in any of the studies evaluated in this review [@b24-cln_69p770].

The disk diffusion test, which was used in only three studies [@b15-cln_69p770],[@b17-cln_69p770],[@b26-cln_69p770], is the simplest and least expensive assay and presents high sensitivity and specificity for detecting MRSA isolates [@b28-cln_69p770]. However, MIC determination and oxacillin agar screening (OAS) were also used to determine the methicillin resistance in several studies [@b9-cln_69p770],[@b15-cln_69p770],. Although these procedures are recommended by CLSI (2009) [@b12-cln_69p770], MIC determination is usually more laborious than other techniques and OAS presents low sensitivity and may be unable to detect SCC*mec* IV isolates [@b28-cln_69p770]. It is important to mention that SCC*mec* IV is traditionally found in community-acquired MRSA isolates and in specific risk groups, such as children, athletes, members of the military and men who have sex with men [@b29-cln_69p770]. However, in this review, only two studies performed SCC*mec* typing and they found that type IV was a common [@b15-cln_69p770] or unique cassette [@b9-cln_69p770] among the analyzed MRSA isolates.

Six studies employed PFGE to verify the clonality of the MRSA isolates obtained from their samples. The USA300 clone was the most common lineage, found in four studies [@b9-cln_69p770],[@b18-cln_69p770],[@b26-cln_69p770],[@b27-cln_69p770], whereas Hidron et al. detected isolates of the USA300 (30.8%), USA100 (40.4%) and USA500 (19.2%) lineages [@b15-cln_69p770]. The USA500 clone was also detected among 15% of MRSA isolates in the study conducted by Gordon et al. [@b17-cln_69p770]. The USA100 and USA500 isolates, which carry SCC*mec* II and I, respectively, were the most common lineages recovered from hospital-acquired infections in the USA and Europe, respectively, in the past decade. However, these lineages are currently being replaced by other lineages that were once limited to the community, such as USA300/SCC*mec* IV [@b30-cln_69p770]. In the USA, where all studies that applied the PFGE technique were conducted, the USA300 clone is considered to be the predominant cause of community-acquired *S. aureus* infections and colonization [@b30-cln_69p770],[@b31-cln_69p770], confirming the findings demonstrating that the USA300 lineage is more frequent among HIV patients. In contrast, in other geographical regions, such as Brazil, Australia and eastern Asia, USA300 is rarely found [@b32-cln_69p770]. In these localities, other lineages are spreading throughout the community [@b30-cln_69p770],[@b33-cln_69p770]. Thus, more studies examining the prevalence of MRSA isolates from HIV patients around the world should be performed to clarify the molecular epidemiology of MRSA isolates recovered from patients in other countries.

The findings of the nine articles selected in this systematic review indicate that the main risk factors for colonization/infection by MRSA in HIV-infected individuals are use of antimicrobials and previous hospitalization. However, the numbers of evaluated patients, the exclusion and inclusion criteria and the characterization of *S. aureus* isolates were not uniform, limiting identification of the characteristics associated with HIV patients who are colonized/infected by *S. aureus*. Infections caused by MRSA isolates are an important issue in the clinical management of HIV patients, so more studies evaluating risk factors and the best techniques to identify and characterize isolates from these patients are necessary.
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###### 

Quality evaluation criteria and their scores.[\*](#tfn1-cln_69p770){ref-type="table-fn"}

  Number   Quality Assessment                                                         Yes   No
  -------- -------------------------------------------------------------------------- ----- ----
  1        Representative sample of the target population                             1     0
  2        Definition of the type of study                                            1     0
  3        Definition of the inclusion and exclusion criteria applied to the sample   1     0
  4        Presence of a control group                                                1     0
  5        Description of risk factors for colonization and/or infection              1     0
  6        Phenotypic analysis: Gram staining and catalase and coagulase tests        1     0
  7        Molecular analysis: SCC*mec* (typing), PFGE and MLST                       1     0
  8        Antimicrobial susceptibility analysis: MIC and disk diffusion tests        1     0
  9        Statistical analysis                                                       1     0
  10       Discussion of the limitations of the study                                 1     0

Based on criteria established by the PRISM statement. SCCmec: staphylococcal cassette chromosome mec; PFGE: pulsed-field gel electrophoresis; MLST: multilocus sequence typing; MIC: minimum inhibitory concentration.

###### 

Databases and search results.

  Reference source                                   Keywords                                                                                                          Total articles   Articles found after applying the inclusion and exclusion criteria   Articles selected based on quality assessment
  -------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ---------------- -------------------------------------------------------------------- -----------------------------------------------
  PubMed                                             HIV[c](#tfn4-cln_69p770){ref-type="table-fn"}; *Staphylococcus*; MRSA[d](#tfn5-cln_69p770){ref-type="table-fn"}   911              23                                                                   9
  SciELO[a](#tfn2-cln_69p770){ref-type="table-fn"}   HIV; *Staphylococcus*; MRSA                                                                                       29               12                                                                   0
  LILACS[b](#tfn3-cln_69p770){ref-type="table-fn"}   HIV; *Staphylococcus*; MRSA                                                                                       841              17                                                                   0
  Ovid                                               HIV; *Staphylococcus*; HIV; MRSA                                                                                  11               5                                                                    0
  Google Scholar                                     MRSA; HIV; recurrent infections; molecular typing; epidemiology                                                   1.115            10                                                                   8

Scientific Electronic Library Online;

Latin American and Caribbean Health Sciences;

human immunodeficiency virus;

methicillin-resistant *Staphylococcus aureus*.

###### 

Characteristics of the nine selected studies involving HIV patients with colonization and/or infection by *Staphylococcus aureus*.

  Type of study (country; authors)                                                    Category (score)   Sample size                                                                  Clinical source(s)                                                                                   Factors associated with colonization and/or infection[\*](#tfn6-cln_69p770){ref-type="table-fn"} by MRSA                                                                                                          Phenotypic analysis of isolates                  Molecular analysis and virulence/resistance genes investigated                                                                                Susceptibility test(s)             Antibiotic resistance rates for *S. aureus* isolates
  ----------------------------------------------------------------------------------- ------------------ ---------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  Case-control(Italy; Tumbarello et al., 2002)                                        A (8)              4,674 HIV-infected patients/129 *S. aureus*/41 MRSA/88 MSSA                  Blood                                                                                                Nosocomial episodes, previous antibiotic therapy and/or bacterial infections                                                                                                                                      API^®^ test ID 32 STAPH                          ND                                                                                                                                            MIC                                CLI 39%; MCL 57%; MET 32%; PEN 73%; QUI 49%; TMP/SXT 70%; VAN 0%
  Case-control (USA; Hidron et al., 2005)                                             A (9)              726 patients/81 HIV-infected patients (14 MRSA)/645 HIV-negative (39 MRSA)   Anterior nares                                                                                       No antimicrobial use in the past three months before the current admission (only for HIV-infected patients)                                                                                                       SMA; latex agglutination test                    PFGE; SCC*mec* typing; PVL                                                                                                                    Disk diffusion; OAS                CLI 32%; DOX 10%; GEN 23%; MCL 92.5%; OXA 100%; QUI 83%; RIF 20%; TMP/SXT 21%; VAN 0% (data from MRSA isolates, independent of patient classification)
  Retrospective case-control (Italy; Drapeau et al., 2007)                            A (8)              3,000 patients/28 MRSA                                                       Blood; skin and soft tissue; sputum, bronchoalveolar lavage and pleural fluids                       T CD4+ T lymphocyte counts \<200 cells/μl; previous hospitalization; an invasive procedure in the previous year                                                                                                   ND                                               ND                                                                                                                                            Automated system                   ND
  Retrospective (USA; Burkey et al., 2008)                                            A (8)              4,607 patients/216 *S. aureus/*94 MRSA                                       Blood                                                                                                Intravenous drug use; CD4+ T lymphocyte counts \<200 cells/μl; end-stage renal disease                                                                                                                            ND                                               ND                                                                                                                                            OAS                                ND
  Prospective (USA; Shet et al., 2009)                                                A (8)              107 patients/41 *S. aureus*/21 MRSA                                          Anterior nares                                                                                       Previous antibiotic therapy                                                                                                                                                                                       SMA; latex agglutination test                    PFGE; SCC*mec* typing; PVL, ACME, *spa*, *mecA*, and *mupA* genes                                                                             MIC                                CLI 43%; MCL 100%; MUP 39%; QUI 95%; TET 24%; TMP/SXT 5%
  Experimental, randomized controlled trial, prospective (USA; Gordon et al., 2010)   A (8)              191 *S. aureus*/27% MRSA                                                     Anterior nares                                                                                       Relapse of drug or alcohol use within the previous month; previous antibiotic therapy                                                                                                                             SMA; latex agglutination test                    PFGE                                                                                                                                          MIC; disk diffusion                CLI 83%; FOX 20%; GEN 9%; MCL 95%; OXA 27%; PEN 99%; QUI 45%; RIF 2%; TET 16%; TMP/SXT 89%; VAN 0%
  Retrospective et al., 2010)                                                         A (8)              900 patients/72 MRSA                                                         Skin or soft tissue and normally sterile sites                                                       Previous antibiotic therapy and/or hospitalization; CD4+ T lymphocyte counts \<200 cells/μl; drug use; hepatitis B co-infection; OI in the previous year; alternative housing\*\*; incarceration; alcohol abuse   ND                                               PFGE                                                                                                                                          ND                                 TMP/STX 2%
  Observational (USA; Popovich et al., 2013)                                          A (8)              745 patients/374 HIV-infected (74 MRSA)/371 HIV-negative (41 MRSA)           Nares; throat; bilateral axillae; bilateral inguinal regions; peri-rectal area and a chronic wound   Incarceration; male gender                                                                                                                                                                                        ChromID MRSA; latex agglutination                PFGE                                                                                                                                          Disk diffusion                     ND
  Cohort (USA; Farley et al., 2013)                                                   A (8)              498 patients/68 HIV-infected (10 MRSA)/430 HIV-negative (20 MRSA)            Anterior nares; axilla and wound                                                                     History of or current abscess; isolation outside the hospital unit; HIV infection (data from all patients, independent of whether they were infected with HIV)                                                    Gram stain; catalase; latex agglutination test   *tufB*, *nuc*, *mecA*, *mupA*, *ileS-2* genes, PVL, TSST-1; PFGE; MLST; an automated platform for pathogen identification and strain typing   CHROMagar MRSA; automated system   TMP/STX 0%; MUP 7.7% (data from MRSA isolates, independent of patient classification)

Factors for which odds ratios and 95% confidence intervals were calculated. ^\*\*^Includes patients residing in personal-care homes, nursing homes, long-term care facilities, and correctional facilities as well as those who were homeless. MRSA: methicillin-resistant *S. aureus*; HIV: human immunodeficiency virus; OI: opportunistic infection; SMA: culture in mannitol salt agar; PFGE: pulsed-field gel electrophoresis; PCR: polymerase chain reaction; PVL: Panton-Valentine leukocidin; TSST1: toxic shock toxin 1; ACME: arginine catabolic mobile element; MIC: minimum inhibitory concentration; CLI: clindamycin; DOX: doxycycline; FOX: cefoxitin; GEN: gentamicin; MCL: macrolides; MET: methicillin; MUP: mupirocin; OXA: oxacillin; PEN: penicillin; QUI: quinolones; RIF: rifampin; TET: tetracycline; TMP/STX: trimethoprim/sulfamethoxazole; VAN: vancomycin; ND: not determined; OAS: oxacillin agar screening.
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